Summit Therapeutics clinical trial updates

What happened: On May 31, Summit Therapeutics (SMMT) announced positive Phase III overall survival data from the HARMONi-6 trial, evaluating ivonescimab plus chemotherapy versus tislelizumab in advanced non-small cell lung cancer (NSCLC). The company also presented Phase II data for AK112-206 in the same week. Cantor Fitzgerald maintained an 'Overweight' rating on SMMT despite mixed clinical developments.

Market impact: The positive HARMONi-6 results drove a 30% increase in SMMT's stock price, benefiting investors with high short interest. The biotechnology sector, particularly companies focused on lung cancer treatments, may see increased interest. However, the mixed results from other trials could limit broader market impact.

What to watch next: Key upcoming catalysts include the release of detailed HARMONi-6 data at an upcoming medical conference, expected in Q3 2023. Additionally, the HARMONi-3 trial's results, evaluating ivonescimab in first-line NSCLC, are anticipated in Q4 2023. These events will significantly influence SMMT's stock performance and the market's perception of its pipeline.